DDInter460 DDInter1676
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cytarabine {u} (Compound) resembles {v} (Compound) Regadenoson
Cytarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Cytarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Cytarabine {u} (Compound) binds {v} (Gene) POLB
Cytarabine {u} (Compound) upregulates {v} (Gene) TICAM1
Cytarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Cytarabine {u} (Compound) downregulates {v} (Gene) KIF4A
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Cytarabine (Compound) resembles Regadenoson (Compound)
Cytarabine (Compound) resembles Nelarabine (Compound)
Cytarabine (Compound) treats hematologic cancer (Disease)
Cytarabine (Compound) binds POLB (Gene)
Cytarabine (Compound) upregulates TICAM1 (Gene)
Cytarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Cytarabine (Compound) downregulates KIF4A (Gene)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin